HONG KONG – Jiangsu, China-based Atom Bioscience and Pharmaceutical Co. Ltd. plans to advance its lead drug candidate – ABP-601 to treat hyperuricemia and gout – into clinical trials in the U.S. after completing a ¥80 million (US$12.3 million) series A round of financing from an undisclosed angel investor.